Telomir Pharmaceuticals has released new preclinical findings indicating that its lead molecule, Telomir-1, can reverse DNA methylation of the CDKN2A gene—a critical tumor suppressor often silenced in aggressive cancers. The company said that in aggressive human prostate cancer cell models (PC3 xenografts), Telomir-1 reduced CDKN2A methylation more effectively than both rapamycin and chemotherapy.
According to the company, by reactivating CDKN2A—the so-called “cell cycle brake” that signals cells to stop dividing and undergo programmed cell death—Telomir-1 may restore a key natural defense against unchecked tumor growth.
These results are said to build on earlier data showing Telomir-1 also resets STAT1, a master regulator of immune surveillance, implying the molecule may counter cancer via dual mechanisms: inhibiting proliferation and enabling immune detection.
The company claims that its pre-IND program is underway, with chemistry, manufacturing and controls (CMC) work scaling up toward GMP production, along with IND-enabling studies as Telomir moves closer to a first Investigational New Drug application.
All statements regarding Telomir-1’s potential as a broad-spectrum DNA methylation reset therapy are attributed to the company and remain at the preclinical stage, with no human data yet available.
